{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T22:49:34Z","timestamp":1767826174797,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T00:00:00Z","timestamp":1326672000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Backgrounds<\/jats:title>\n            <jats:p>There have been conflicting reports about serum golgi protein 73 (GP73) as one of the most promising serum markers for the diagnosis of hepatocellular carcinoma (HCC). This study was to make a systematic review about the diagnostic accuracy of serum GP73 versus alpha-fetoprotein (AFP) for HCC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>After a systematic review of related studies, sensitivity, specificity and other measures about the accuracy of serum GP73 and AFP in the diagnosis of HCC were pooled using random-effects models. Summary receiver operating characteristic curve analysis was used to summarize the overall test performance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Eight studies were included in our meta-analysis. The summary estimates for serum GP73 and AFP in diagnosing HCC in the studies included were as follows: sensitivity, 76% (95% confidence interval (CI) 51-91%) vs. 70% (47-86%); specificity, 86% (95%CI 65-95%) vs. 89% (69-96%); diagnostic odds ratio (DOR), 18.59 (95%CI 5.33-64.91) vs. 18.00(9.41-34.46); and area under sROC, 0.88 (95%CI 0.77-0.99) vs. 0.86 (95%CI 0.84-0.87).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The current evidence indicates that serum GP73 has a comparable accuracy to AFP for the diagnosis of HCC, while the value of serum GP73 in combination with AFP for HCC detection deserves further investigation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-12-17","type":"journal-article","created":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T07:26:52Z","timestamp":1326785212000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta- analysis"],"prefix":"10.1186","volume":"12","author":[{"given":"Ying","family":"Zhou","sequence":"first","affiliation":[]},{"given":"Xin","family":"Yin","sequence":"additional","affiliation":[]},{"given":"Jun","family":"Ying","sequence":"additional","affiliation":[]},{"given":"BoHeng","family":"Zhang","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2012,1,16]]},"reference":[{"key":"3039_CR1","volume-title":"GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer","author":"J Ferlay","year":"2010","unstructured":"Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer. 2010, [http:\/\/globocan.iarc.fr]"},{"issue":"Suppl1","key":"3039_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1053\/j.gastro.2004.09.014","volume":"127","author":"G Fattovich","year":"2004","unstructured":"Fattovich G, Stroffolini T, Zagni I, Donato F: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004, 127 (Suppl1): 35-50.","journal-title":"Gastroenterology"},{"key":"3039_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/hep.1840190111","volume":"19","author":"H Oka","year":"1994","unstructured":"Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S: Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 1994, 19: 61-67. 10.1002\/hep.1840190111.","journal-title":"Hepatology"},{"key":"3039_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0168-8278(05)80468-4","volume":"20","author":"D Pateron","year":"1994","unstructured":"Pateron D, Ganne N, Trinchet JC, Aurousseau MH, Mal F, Meicler C, Coderc E, Reboullet P, Beaugrand M: Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol. 1994, 20: 65-71. 10.1016\/S0168-8278(05)80468-4.","journal-title":"J Hepatol"},{"key":"3039_CR5","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/(SICI)1097-0142(19960901)78:5<977::AID-CNCR6>3.0.CO;2-9","volume":"78","author":"M Zoli","year":"1996","unstructured":"Zoli M, Magalotti D, Bianchi G, Gueli C, Marchesini G, Pisi E: Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer. 1996, 78: 977-983. 10.1002\/(SICI)1097-0142(19960901)78:5<977::AID-CNCR6>3.0.CO;2-9.","journal-title":"Cancer"},{"key":"3039_CR6","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1515\/CCLM.2007.262","volume":"45","author":"R Saffroy","year":"2007","unstructured":"Saffroy R, Pham P, Reffas M, Takka M, Lemoine A, Debuire B: New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med. 2007, 45: 1169-1179. 10.1515\/CCLM.2007.262.","journal-title":"Clin Chem Lab Med"},{"key":"3039_CR7","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1073\/pnas.0408928102","volume":"102","author":"TM Block","year":"2005","unstructured":"Block TM, Comunale MA, Lowman M, Steel LF, Romano PR, Fimmel C, Tennant BC, London WT, Evans AA, Blumberg BS, et al: Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci. 2005, 102: 779-784. 10.1073\/pnas.0408928102.","journal-title":"Proc Natl Acad Sci"},{"key":"3039_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2288-3-25","volume":"3","author":"P Whiting","year":"2003","unstructured":"Whiting P, Rutjes AWS, Reitsma JB, Bossuyt PM, Kleijnen J: The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Medical Res Methodology. 2003, 3: 25-10.1186\/1471-2288-3-25.","journal-title":"BMC Medical Res Methodology"},{"key":"3039_CR9","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","volume":"35","author":"J Bruix","year":"2001","unstructured":"Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J, EASL Panel of Experts on HCC: Clinical management of hepatocellular carcinoma, conclusions of the Barcelona-2000 EASL conference. J Hepatol. 2001, 35: 421-430. 10.1016\/S0168-8278(01)00130-1.","journal-title":"J Hepatol"},{"key":"3039_CR10","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.11569\/wcjd.v17.i29.3056","volume":"17","author":"LJ Li","year":"2009","unstructured":"Li LJ, Li XF, Wang GX: Significance of Golgi protein 73, alpha-fetoprotein and vascular endothelial growth factor expression in diagnosis of primary hepatic cancer. World Chinese J Digestology. 2009, 17: 3056-3060.","journal-title":"World Chinese J Digestology"},{"key":"3039_CR11","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/hep.23053","volume":"50","author":"MO Riener","year":"2009","unstructured":"Riener MO, Stenner F, Liewen H, Hellerbrand C, Bahra M, Kristiansen G: Alpha-fetoprotein and serum golgi phosphoprotein 2 are equally discriminative in detecting early hepatocellular carcinomas. Hepatology. 2009, 50: 326-","journal-title":"Hepatology"},{"issue":"SUPPL","key":"3039_CR12","first-page":"1096A","volume":"50","author":"K Yamamoto","year":"2009","unstructured":"Yamamoto K, Imamura H, Matsuyama Y, Ikeda H, Norman GL, Shums Z, Aoki T, Hasegawa K, Beck Y, Sugawawa Y, et al: A prospective study of measurements of four tumor markers in patients with hepatocellular carcinoma (HCC). Hepatology. 2009, 50 (SUPPL): 1096A-","journal-title":"Hepatology"},{"key":"3039_CR13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S1359-6349(09)71376-X","volume":"7","author":"F Stenner","year":"2009","unstructured":"Stenner F, Heike Liewen HL, Panagiotis Samaras PS, Holger Moch HM, Alexander Knuth AK, Marc-Oliver Riener MOR, Kristiansen G, Renner C, Bahra M, Hellerbrand C: The emerging role of the novel serum marker GOLPH2 in detecting and monitoring of hepatocellular carcinoma. European J Cancer. 2009, 7: 404-405.","journal-title":"European J Cancer"},{"key":"3039_CR14","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1007\/s00535-010-0278-5","volume":"45","author":"K Yamamoto","year":"2010","unstructured":"Yamamoto K, Imamura H, Matsuyama Y, Kume Y, Ikeda H, Norman GL, Shums Z, Aoki T, Hasegawa K, Beck Y, et al: AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol. 2010, 45: 1272-1282. 10.1007\/s00535-010-0278-5.","journal-title":"J Gastroenterol"},{"key":"3039_CR15","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1002\/hep.22843","volume":"49","author":"MO Riener","year":"2009","unstructured":"Riener MO, Stenner F, Liewen H, Hellerbrand C, Bahra M, Kristiansen G: Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology. 2009, 49: 1602-1609. 10.1002\/hep.22843.","journal-title":"Hepatology"},{"key":"3039_CR16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/hep.23028","volume":"50","author":"X Li","year":"2009","unstructured":"Li X, Wu K, Fan D: Serum Golgi phosphoprotein 2 level: A better marker than alpha-fetoprotein for diagnosing early hepatocellular carcinoma. Hepatology. 2009, 50: 325-10.1002\/hep.23028.","journal-title":"Hepatology"},{"key":"3039_CR17","first-page":"288","volume":"17","author":"LY Tan","year":"2009","unstructured":"Tan LY, Chen J, Wang H, Ye HQ, Li Q, Gu JA, Han LQ: Correlation between serum Golph2 protein and hepatocellular carcinoma. Chinese J Hepatol. 2009, 17: 288-291.","journal-title":"Chinese J Hepatol"},{"key":"3039_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1258\/acb.2008.008088","volume":"46","author":"Y Gu","year":"2009","unstructured":"Gu Y, Chen W, Zhao Y, Chen L, Peng T: Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases. Ann Clin Biochem. 2009, 46: 38-43. 10.1258\/acb.2008.008088.","journal-title":"Ann Clin Biochem"},{"key":"3039_CR19","first-page":"948","volume":"88","author":"YL Mao","year":"2008","unstructured":"Mao YL, Yang HY, Xu HF, Sang XT, Lu X, Yang ZY, Zhang JC, Zhong SX, Huang JF, Zhang HB: Significance of Golgi glycoprotein 73, a new tumor marker in diagnosis of hepatocellular carcinoma: a primary study. Zhonghua Yi Xue Za Zhi. 2008, 88: 948-951.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"3039_CR20","first-page":"39","volume":"33","author":"W Chen","year":"2011","unstructured":"Chen W, Yang HY, Mao YL, Zhang JC, Xu HF, Jiang GY, Jin YL, Chen XX, Lu X, Sang XT, et al: Value of Golgi protein 73 monoclonal antibody in diagnosis of hepatocellular carcinoma. Acta Academiae Medicinae Sinicae. 2011, 33: 39-44.","journal-title":"Acta Academiae Medicinae Sinicae"},{"key":"3039_CR21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.7785\/tcrt.2012.500205","volume":"10","author":"Y Shi","year":"2011","unstructured":"Shi Y, Chen J, Li L, Sun Z, Zen L, Xu S, Zhang Y, Zhang L: A study of diagnostic value of Golgi protein GP73 and its genetic assay in primary hepatic carcinoma. Technol Cancer Res Treat. 2011, 10: 287-294.","journal-title":"Technol Cancer Res Treat"},{"key":"3039_CR22","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s12032-009-9215-y","volume":"27","author":"JS Hu","year":"2010","unstructured":"Hu JS, Wu DW, Liang S, Miao XY: GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med Oncol. 2010, 27: 339-345. 10.1007\/s12032-009-9215-y.","journal-title":"Med Oncol"},{"key":"3039_CR23","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1515\/CCLM.2011.097","volume":"49","author":"K Morota","year":"2011","unstructured":"Morota K, Morota K, Nakagawa M, Sekiya R, Hemken PM, Sokoll LJ, Elliott D, Chan DW, Dowell BL: A comparative evaluation of Golgi protein-73, fucosylated hemopexin, (alpha)-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Clin Chem Lab Med. 2011, 49: 711-718. 10.1515\/CCLM.2011.097.","journal-title":"Clin Chem Lab Med"},{"key":"3039_CR24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000320379","volume":"83","author":"H Ozkan","year":"2010","unstructured":"Ozkan H, Erdal H, Tutkak H, Karaeren Z, Yakut M, Yuksel O, Koklu S: Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma. Digestion. 2010, 83: 83-88.","journal-title":"Digestion"},{"key":"3039_CR25","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1136\/gut.2010.214916","volume":"59","author":"Y Mao","year":"2010","unstructured":"Mao Y, Yang H, Xu H, Lu X, Sang X, Du S, Zhao H, Chen W, Xu Y, Chi T, et al: Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut. 2010, 59: 1687-1693. 10.1136\/gut.2010.214916.","journal-title":"Gut"},{"key":"3039_CR26","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.jhep.2005.05.028","volume":"43","author":"JA Marrero","year":"2005","unstructured":"Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, Comunale MA, D'Amelio A, Lok AS, Block TM: GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol. 2005, 43: 1007-1012. 10.1016\/j.jhep.2005.05.028.","journal-title":"J Hepatol"},{"key":"3039_CR27","first-page":"6","volume":"7","author":"L Tian","year":"2011","unstructured":"Tian L, Wang Y, Xu D, Gui J, Jia X, Tong H, Wen X, Dong Z, Tian Y: Serological AFP\/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases. Int J Cancer. 2011, 7: 6-","journal-title":"Int J Cancer"},{"key":"3039_CR28","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1158\/1055-9965.EPI-08-0980","volume":"18","author":"M Wang","year":"2009","unstructured":"Wang M, Long RE, Comunale MA, Junaidi O, Marrero J, Di Bisceglie AM, Block TM, Mehta AS: Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers and Prev. 2009, 18: 1914-1921. 10.1158\/1055-9965.EPI-08-0980.","journal-title":"Cancer Epidemiol Biomarkers and Prev"},{"key":"3039_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1471-2288-5-19","volume":"5","author":"P Whiting","year":"2005","unstructured":"Whiting P, Harbord R, Kleijnen J: No role for quality scores in systematic reviews of diagnostic accuracy studies. BMC Med Res Methodol. 2005, 5: 19-10.1186\/1471-2288-5-19.","journal-title":"BMC Med Res Methodol"},{"key":"3039_CR30","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/bmj.323.7305.157","volume":"323","author":"JJ Deeks","year":"2001","unstructured":"Deeks JJ: Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ. 2001, 323: 157-62.","journal-title":"BMJ"},{"key":"3039_CR31","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1002\/sim.1099","volume":"21","author":"SD Walter","year":"2002","unstructured":"Walter SD: Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med. 2002, 21: 1237-56. 10.1002\/sim.1099.","journal-title":"Stat Med"},{"key":"3039_CR32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0378-1119(00)00136-0","volume":"249","author":"RD Kladney","year":"2000","unstructured":"Kladney RD, Bulla GA, Guo L, Mason AL, Tollefson AE, Simon DJ, Koutoubi Z, Fimmel CJ: GP73, a novel Golgi-localized protein upregulated by viral infection. Gene. 2000, 249: 53-65. 10.1016\/S0378-1119(00)00136-0.","journal-title":"Gene"},{"issue":"suppl1","key":"3039_CR33","first-page":"406A","volume":"46","author":"A Sangiovanni","year":"2007","unstructured":"Sangiovanni A, Romeo R, Prati GM, Manini MA, Lavarone M, Ronchi G, Colombo M: Serum expression of lectin reactive \u03b1-fetoprotein, des-\u03b3-carboxy prothrombin, Golgi protein-73 antigen and antibody, for the diagnosis of hepatocellular carcinoma [abstract]. Hepatology. 2007, 46 (suppl1): 406A-","journal-title":"Hepatology"},{"key":"3039_CR34","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/pmic.200300625","volume":"4","author":"MA Comunale","year":"2004","unstructured":"Comunale MA, Mattu TS, Lowman MA, Evans AA, London WT, Semmes OJ, Ward M, Drake R, Romano PR, Steel LF, Block TM, Mehta A: Comparative proteomic analysis of de-N-glycosylated serum from hepatitis B carriers reveals polypeptides that correlate with disease status. Proteomics. 2004, 4: 826-838. 10.1002\/pmic.200300625.","journal-title":"Proteomics"},{"key":"3039_CR35","doi-asserted-by":"crossref","unstructured":"Phases of Biomarker Development for Early Detection of Cancer. J National Cancer Inst. 2001, 93: 1054-61. 10.1093\/jnci\/93.14.1054.","DOI":"10.1093\/jnci\/93.14.1054"},{"key":"3039_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cdp.2006.11.003","volume":"31","author":"LM Wright","year":"2007","unstructured":"Wright LM, Kreikemeier JT, Fimmel CJ: A concise review of serum markers for hepatocellular cancer. Cancer Detection and Prev. 2007, 31: 35-44. 10.1016\/j.cdp.2006.11.003.","journal-title":"Cancer Detection and Prev"},{"key":"3039_CR37","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1002\/sim.1091","volume":"20","author":"DB Petitti","year":"2001","unstructured":"Petitti DB: Approaches to heterogeneity in meta-analysis. Stat Med. 2001, 20: 3625-33. 10.1002\/sim.1091.","journal-title":"Stat Med"},{"key":"3039_CR38","doi-asserted-by":"publisher","first-page":"189","DOI":"10.7326\/0003-4819-140-3-200402030-00010","volume":"140","author":"P Whiting","year":"2004","unstructured":"Whiting P, Rutjes AW, Reitsma JB, Glas AS, Bossuyt PMM, Kleijnen J: Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med. 2004, 140: 189-202.","journal-title":"Ann Intern Med"},{"key":"3039_CR39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1258\/1355819021927674","volume":"7","author":"J Higgins","year":"2002","unstructured":"Higgins J, Thompson S, Deeks J, Altman D: Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Services Res and Policy. 2002, 7: 51-61. 10.1258\/1355819021927674.","journal-title":"J Health Services Res and Policy"},{"key":"3039_CR40","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1093\/ije\/31.1.88","volume":"31","author":"F Song","year":"2002","unstructured":"Song F, Khan KS, Dinnes J, Sutton AJ: Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol. 2002, 31: 88-95. 10.1093\/ije\/31.1.88.","journal-title":"Int J Epidemiol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-17.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-12-17\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-17.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T20:27:24Z","timestamp":1630614444000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-12-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,16]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["3039"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-12-17","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,16]]},"assertion":[{"value":"6 July 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"17"}}